electroCore, Inc. $ECOR Shares Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC increased its stake in shares of electroCore, Inc. (NASDAQ:ECOR) by 65.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 77,020 shares of the company’s stock after purchasing an additional 30,550 shares during the period. International Assets Investment Management LLC owned 1.03% of electroCore worth $407,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. AWM Investment Company Inc. raised its holdings in electroCore by 95.0% in the 1st quarter. AWM Investment Company Inc. now owns 318,106 shares of the company’s stock valued at $2,128,000 after acquiring an additional 154,973 shares during the last quarter. NewEdge Advisors LLC raised its holdings in electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock valued at $1,083,000 after acquiring an additional 145,047 shares during the last quarter. Jane Street Group LLC raised its holdings in electroCore by 114.4% in the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after acquiring an additional 19,599 shares during the last quarter. Jaffetilchin Investment Partners LLC raised its holdings in electroCore by 25.5% in the 1st quarter. Jaffetilchin Investment Partners LLC now owns 32,983 shares of the company’s stock valued at $221,000 after acquiring an additional 6,700 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in electroCore in the 1st quarter valued at about $153,000. Institutional investors and hedge funds own 26.74% of the company’s stock.

Insider Buying and Selling at electroCore

In other news, Director Thomas J. Errico acquired 15,000 shares of electroCore stock in a transaction dated Monday, August 11th. The shares were acquired at an average cost of $4.47 per share, for a total transaction of $67,050.00. Following the acquisition, the director owned 281,401 shares of the company’s stock, valued at $1,257,862.47. This trade represents a 5.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 13.80% of the company’s stock.

electroCore Stock Down 2.8%

Shares of ECOR stock opened at $4.83 on Thursday. electroCore, Inc. has a 52 week low of $4.16 and a 52 week high of $19.49. The stock has a market capitalization of $38.64 million, a PE ratio of -2.98 and a beta of 0.34. The firm has a 50 day moving average of $5.08 and a two-hundred day moving average of $5.67.

electroCore (NASDAQ:ECOR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). electroCore had a negative net margin of 47.84% and a negative return on equity of 221.93%. The firm had revenue of $7.38 million during the quarter, compared to analyst estimates of $7.24 million. Analysts expect that electroCore, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ECOR. Weiss Ratings reiterated a “sell (e+)” rating on shares of electroCore in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of electroCore from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, electroCore presently has a consensus rating of “Hold” and an average target price of $25.50.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.